<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Boixadera, Anna</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-Term Ranibizumab Effective in Diabetic Macular Edema</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-13</style></pages><abstract><style  face="normal" font="default" size="100%">In patients with diabetic macular edema, long-term intravitreal injections of ranibizumab maintains best-corrected visual acuity and central retinal subfield thickness improvements over 36 months, with no new or increased safety concerns. This article discusses the final analysis of the 36-month study comprising: A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-Label Extension Study [RESTORE; NCT00687804].</style></abstract><number><style face="normal" font="default" size="100%">17</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>